BPC-157

What is BPC-157

BPC-157 stands for Body Protection Compound 157. It is a synthetic pentadecapeptide of 15 amino acids, originally isolated from human gastric juice. The research group around Predrag Sikiric in Zagreb described the molecule for the first time in 1991 and continues to advance research today. The sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is derived from a larger body-specific protective protein in the stomach.

Molecular weight: 1419.53 g/mol. CAS No: 137525-51-0. In the research literature it also appears as PL 14736 or bepecin. BPC-157 does not have a pharmaceutical license, but is documented in over 200 published preclinical studies. A clinical trial of patients with inflammatory bowel disease ran in the early 2000s but remained unfinished.

Mechanism of action

The exact mechanism is not fully clarified. The most plausible hypothesis: BPC-157 modulates several signalling pathways at the same time instead of binding a single receptor.

The focus is on promoting angiogenesis. BPC-157 increases the expression of VEGF (Vascular Endothelial Growth Factor) and stimulates the formation of new blood vessels in the injured tissue. This greatly accelerates the healing of tendons, ligaments and muscle tissue in animal models.

In addition, there is evidence of modulation of the nitric oxide (NO) system, of the dopamine and serotonin signalling pathways in the gastrointestinal tract and of interaction with the growth hormone receptor. In recent work (Sikiric et al., 2020 ff.) a concept of the "cytoprotective effect" is discussed: BPC-157 stabilizes cell membranes, promotes mitochondrial function and reduces oxidative stress.

Human studies are largely lacking. This is the central limitation.

Areas of application in research

tendon and ligament healing: Achilles tendon repair, cruciate ligament models (rat)
Gastrointestinal tract Protection against NSAID-induced ulcers, IBD models
Muscle regeneration: Injury models, muscle fiber recovery
Neuroprotection: Stroke models, brain trauma in animals
Bone and joint healing: Fracture models, osteoarthritis
Periodontal healing: Animal gum regeneration
Cardiovascular effects: Stabilisation in experimental heart failure

Study situation

The data is extensive, but asymmetric: much animal, hardly human.

Important preclinical work:

Sikiric et al. (Current Pharmaceutical Design, 2010): Review of the first 20 years, establishes the pleiotropic action profile
Chang et al. (Journal of Applied Physiology, 2011): Achilles tendon healing in rats, significant improvement in tensile strength
Huang et al. (PLoS One, 2015): Accelerated muscle regeneration after injury in mice
Sikiric et al. (Frontiers in Pharmacology, 2020): Update review on the cytoprotective hypothesis

Human studies: A phase 2 study on PL 14736 (equivalent to BPC-157) in IBD was initiated by Pliva (now Teva), but not published in full. Except for a few conference abstracts, there is no peer-reviewed human study with hard endpoints.

What is clear: consistent healing effects in the animal across many tissue types. What is unclear: whether these effects occur in humans in comparable strength, optimal dose in humans, long-term safety.

Mixing (reconstitution)

Typical Vial sizes: 2 mg, 5 mg, 10 mg lyophilisate.

5-mg Vial with 2 ml of bacteriostatic water → 2.5 mg/ml (corresponds to 250 mcg per 0.1 ml)
5-mg Vial with 2.5 ml → 2 mg/ml
10 mg Vial with 2 ml → 5 mg/ml for higher concentrations

Bacteriostatic water is preferred because of benzyl alcohol conservation. After mixing, cooling at 2 to 8 degrees, stability about 4 to 6 weeks. Lyophilisateeeee unopened stable at -20 degrees over years, at 2 to 8 degrees at least 24 months.

Dosage range (research data)

Animal studies usually use 10 mcg/kg per day, intraperitoneally or Orally. These data and researcher references result in the following theoretical ranges for the human equivalent dose:

Lower range: 200 mcg per day
Medium range: 250 to 500 mcg per day
Upper range: up to 1000 mcg per day in divided doses
Forms of administration in practice: subcutaneous, intramuscular, Oral (Oral bioavailability controversial)
Cycle length typical: 4 to 8 weeks, then break

These figures are research references, not recommendations for use in humans.

Side effects

In animal studies, BPC-157 shows a remarkably clean profile. No relevant toxicity was observed at the most commonly used doses. Sikiric does not describe mortality or organ toxicity even with multiple multiplication of the standard dose.

In humans, controlled data is lacking. Anecdotal reports from the self-application community (no scientific value, but mention important):

Slight irritation at the injection site
Temporary fatigue
Occasional headache
In isolated cases, reports of changes in heart rate

The pro-angiogenic profile is a theoretical risk in active tumors because tumors need angiogenesis for growth. Data is completely missing here.

Half-Life and Pharmacokinetics

BPC-157 is small and peptidic, so the plasma half-life is short, in the range of minutes. Nevertheless, the biological effect appears to last significantly longer, indicating a longer tissue retention or trigger effect on downstream processes.

Oral bioavailability is controversial. Sikiric group argues for relevant Oral efficacy via local gastrointestinal effects and also postulates a systemic component. Independent confirmation of Oral bioavailability is missing.

Types of administration in animal studies: intraperitoneal, intragastral, local. In the self-application community, subcutaneous and intramuscular injections dominate.

Frequent questions

Does BPC-157 really help with tendon injuries? Consistent in the animal yes. In humans without a controlled study. Anecdotal reports are plentiful but scientifically unreliable.

Is Oral BPC-157 Effective? Probably for local GI effects yes, for systemic effects unclear. Those who aim for systemic effect usually choose the injection in research.

How long a cycle? Research standard cycles are 4 to 8 weeks. Longer application without hard data.

Can I combine BPC-157 with TB-500? In the healing peptide community often combined, theoretically complementary (BPC-157 promotes angiogenesis, TB-500 cell migration). Studies on the combination are missing.

Why is BPC-157 not approved if it works so well? Because a full phase 2/3 human study was never completed. Without this data, approval is impossible, regardless of how convincing the animal data is.

Legal status U.S.

As of 2026: BPC-157 is not an approved medicine in Germany, Austria and Switzerland. It falls under the Medicines Act if it is used for therapeutic purposes. Research-use-only distribution exists in a legal grey area.

WADA (Whererld Anti-Doping Agency) has explicitly put BPC-157 2022 on the prohibited list (S0 category: non-approved substances). For athletes under doping control, use is therefore clearly prohibited.

Own import from abroad: §73 AMG problem. Customs controls are real.

Related compounds

TB-500 (thymosin beta-4)Complementary healing peptide, often combined
KPVTripeptide with anti-inflammatory action
PEA (palmitoylethanolamide)Endogenous fatty acid amide, anti-inflammatory
GHK CuCopper peptide with regenerative effect on skin and tissue
LL-37Antimicrobial peptide with wound healing effects

Note: All information is for research information only. These peptides are not approved as medicines in Germany. The contents do not replace medical advice. Application to humans is not legally covered in Germany.